Back to: products

Europe Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule)

PrintEmail
Jul 2021 - 111 Pages - From $2,900
(Excel Data Sheet: $1,500)
Description

The report cover may be different from the image shown.

Product and Price

By clicking the Add to Shopping Cart button, you certify to agree with our Terms of Service.

Europe multiple sclerosis drugs market accounted for $5,668.0 million in 2020 and will grow by 4.2% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs.
Highlighted with 38 tables and 55 figures, this 111-page report “Europe Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire Europe multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe multiple sclerosis drugs market in every aspect of the classification from perspectives of Drug Type, Drug Class, Drug Category, Route of Administration, MS Type, Distribution Channel, and Country.

Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Immunomodulators
o Copaxone
o Avonex/Plegridy
o Gilneya
o Tysabri
o Betaseron/Extavia
o Tecifidera
o Rebif
o Ampyra
o Other Immunomodulators
• Immunosuppressants
o Aubagio
o Lemtrada
o Ocrelizumab
o Zinbryta
o Other Immunosuppressants

Based on Drug Class, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Monoclonal Antibodies
• Interferon Beta
• Sphingosine 1 Phosphate Receptor Modulators
• Mixed Polymers
• NF-κB Inhibitor
• Pyrimidine Synthesis Inhibitor
• Corticosteroids
• Adrenocorticotropic Hormone
• Other Drug Classes

Based on Drug Category, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Large-molecule Drugs
• Small-molecule Drugs

Based on Route of Administration, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Oral Administration
• Parenteral Administration

Based on MS Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Relapsing-remitting MS (RRMS)
• Primary-progressive MS (PPMS)
• Secondary-progressive MS (SPMS)
• Progressive-relapsing MS (PRMS)

Based on Distribution Channel, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbvie, Inc.
Acorda Therapeutics Inc.
Bayer AG
Biogen Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Merck KgaA
Mylan NV
Novartis AG
Pfizer Inc.
Sanofi SA
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 22
2.2 Major Growth Drivers 24
2.3 Market Restraints and Challenges 29
2.4 Emerging Opportunities and Market Trends 33
2.5 Porter’s Fiver Forces Analysis 37
3 Segmentation of Europe Market by Drug Type 41
3.1 Market Overview by Drug Type 41
3.2 Immunomodulators 43
3.3 Immunosuppressants 45
4 Segmentation of Europe Market by Drug Class 47
4.1 Market Overview by Drug Class 47
4.2 Monoclonal Antibodies 49
4.3 Interferon Beta 50
4.4 Sphingosine 1 Phosphate Receptor Modulators 51
4.5 Mixed Polymers 52
4.6 NF-κB Inhibitor 53
4.7 Pyrimidine Synthesis Inhibitor 54
4.8 Corticosteroids 55
4.9 Adrenocorticotropic Hormone 56
4.10 Other Drug Classes 57
5 Segmentation of Europe Market by Drug Category 58
5.1 Market Overview by Drug Category 58
5.2 Large-molecule Drugs 60
5.3 Small-molecule Drugs 61
6 Segmentation of Europe Market by Route of Administration 62
6.1 Market Overview by Route of Administration 62
6.2 Oral Administration 64
6.3 Parenteral Administration 65
7 Segmentation of Europe Market by MS Type 66
7.1 Market Overview by MS Type 66
7.2 Relapsing-remitting MS (RRMS) 68
7.3 Primary-progressive MS (PPMS) 69
7.4 Secondary-progressive MS (SPMS) 70
7.5 Progressive-relapsing MS (PRMS) 71
8 Segmentation of Europe Market by Distribution Channel 72
8.1 Market Overview by Distribution Channel 72
8.2 Hospital Pharmacies 74
8.3 Retail Pharmacies 75
8.4 Online Pharmacies 76
9 European Market 2020-2027 by Country 77
9.1 Overview of European Market 77
9.2 UK 80
9.3 France 82
9.4 Germany 84
9.5 Spain 86
9.6 Italy 88
9.7 Russia 90
9.8 Rest of European Market 92
10 Competitive Landscape 94
10.1 Overview of Key Vendors 94
10.2 New Product Launch, Partnership, Investment, and M&A 97
10.3 Company Profiles 98
Abbvie, Inc. 98
Acorda Therapeutics Inc. 100
Bayer AG 101
Biogen Inc. 102
Bristol-Myers Squibb Company 103
F. Hoffmann-La Roche Ltd. 104
Merck KgaA 105
Mylan NV 106
Novartis AG 107
Pfizer Inc. 108
Sanofi SA 109
Teva Pharmaceutical Industries Ltd. 110
RELATED REPORTS 111

List of Tables:

Table 1. Snapshot of Europe Multiple Sclerosis Drugs Market in Balanced Perspective, 2020-2027 17
Table 2. Growth Rate of World GDP, 2020-2022 21
Table 3. World Health Spending by Region, $ bn, 2013-2020 28
Table 4. Price Comparison of Commonly Used Multiple Sclerosis Medications 31
Table 5. Main Adverse Effects of Multiple Sclerosis Drugs 32
Table 6. Main Product Trends and Market Opportunities in Europe Multiple Sclerosis Drugs Market 33
Table 7. Europe Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 41
Table 8. Europe Multiple Sclerosis Drugs Market: Immunomodulators by Drug, 2017-2027, $ mn 44
Table 9. Europe Multiple Sclerosis Drugs Market: Immunosuppressants by Drug, 2017-2027, $ mn 46
Table 10. Europe Multiple Sclerosis Drugs Market by Drug Class, 2017-2027, $ mn 47
Table 11. Europe Multiple Sclerosis Drugs Market by Drug Category, 2017-2027, $ mn 58
Table 12. Europe Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 62
Table 13. Europe Multiple Sclerosis Drugs Market by MS Type, 2017-2027, $ mn 66
Table 14. Europe Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 72
Table 15. Europe Multiple Sclerosis Drugs Market by Country, 2017-2027, $ mn 79
Table 16. UK Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 81
Table 17. UK Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 81
Table 18. UK Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 81
Table 19. France Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 83
Table 20. France Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 83
Table 21. France Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 83
Table 22. Germany Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 85
Table 23. Germany Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 85
Table 24. Germany Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 85
Table 25. Spain Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 87
Table 26. Spain Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 87
Table 27. Spain Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 87
Table 28. Italy Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 89
Table 29. Italy Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 89
Table 30. Italy Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 89
Table 31. Russia Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 91
Table 32. Russia Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 91
Table 33. Russia Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 91
Table 34. Multiple Sclerosis Drugs Market in Rest of Europe by Country, 2017-2027, $ mn 93
Table 35. Abbvie, Inc.: Company Snapshot 98
Table 36. Abbvie, Inc.: Business Segmentation 98
Table 37. Abbvie, Inc.: Product Portfolio 99
Table 38. Abbvie, Inc.: Revenue, 2017-2019, $ mn 99

 

 

List of Figures:

Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 16
Figure 4. Europe Multiple Sclerosis Drugs Market, 2017-2027, $ mn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of Europe Multiple Sclerosis Drugs Market 24
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 27
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 27
Figure 9. Primary Restraints and Impact Factors of Europe Multiple Sclerosis Drugs Market 29
Figure 10. Investment Opportunity Analysis 34
Figure 11. Porter’s Fiver Forces Analysis of Europe Multiple Sclerosis Drugs Market 37
Figure 12. Breakdown of Europe Multiple Sclerosis Drugs Market by Drug Type, 2020-2027, % of Revenue 41
Figure 13. Contribution to Europe 2021-2027 Cumulative Revenue by Drug Type, Value ($ mn) and Share (%) 42
Figure 14. Europe Multiple Sclerosis Drugs Market: Immunomodulators, 2017-2027, $ mn 43
Figure 15. Europe Multiple Sclerosis Drugs Market: Immunosuppressants, 2017-2027, $ mn 45
Figure 16. Breakdown of Europe Multiple Sclerosis Drugs Market by Drug Class, 2020-2027, % of Revenue 48
Figure 17. Contribution to Europe 2021-2027 Cumulative Revenue by Drug Class, Value ($ mn) and Share (%) 48
Figure 18. Europe Multiple Sclerosis Drugs Market: Monoclonal Antibodies, 2017-2027, $ mn 49
Figure 19. Europe Multiple Sclerosis Drugs Market: Interferon Beta, 2017-2027, $ mn 50
Figure 20. Europe Multiple Sclerosis Drugs Market: Sphingosine 1 Phosphate Receptor Modulators, 2017-2027, $ mn 51
Figure 21. Europe Multiple Sclerosis Drugs Market: Mixed Polymers, 2017-2027, $ mn 52
Figure 22. Europe Multiple Sclerosis Drugs Market: NF-κB Inhibitor, 2017-2027, $ mn 53
Figure 23. Europe Multiple Sclerosis Drugs Market: Pyrimidine Synthesis Inhibitor, 2017-2027, $ mn 54
Figure 24. Europe Multiple Sclerosis Drugs Market: Corticosteroids, 2017-2027, $ mn 55
Figure 25. Europe Multiple Sclerosis Drugs Market: Adrenocorticotropic Hormone, 2017-2027, $ mn 56
Figure 26. Europe Multiple Sclerosis Drugs Market: Other Drug Classes, 2017-2027, $ mn 57
Figure 27. Breakdown of Europe Multiple Sclerosis Drugs Market by Drug Category, 2020-2027, % of Revenue 58
Figure 28. Contribution to Europe 2021-2027 Cumulative Revenue by Drug Category, Value ($ mn) and Share (%) 59
Figure 29. Europe Multiple Sclerosis Drugs Market: Large-molecule Drugs, 2017-2027, $ mn 60
Figure 30. Europe Multiple Sclerosis Drugs Market: Small-molecule Drugs, 2017-2027, $ mn 61
Figure 31. Breakdown of Europe Multiple Sclerosis Drugs Market by Route of Administration, 2020-2027, % of Revenue 62
Figure 32. Contribution to Europe 2021-2027 Cumulative Revenue by Route of Administration, Value ($ mn) and Share (%) 63
Figure 33. Europe Multiple Sclerosis Drugs Market: Oral Administration, 2017-2027, $ mn 64
Figure 34. Europe Multiple Sclerosis Drugs Market: Parenteral Administration, 2017-2027, $ mn 65
Figure 35. Breakdown of Europe Multiple Sclerosis Drugs Market by MS Type, 2020-2027, % of Revenue 66
Figure 36. Contribution to Europe 2021-2027 Cumulative Revenue by MS Type, Value ($ mn) and Share (%) 67
Figure 37. Europe Multiple Sclerosis Drugs Market: Relapsing-remitting MS (RRMS), 2017-2027, $ mn 68
Figure 38. Europe Multiple Sclerosis Drugs Market: Primary-progressive MS (PPMS), 2017-2027, $ mn 69
Figure 39. Europe Multiple Sclerosis Drugs Market: Secondary-progressive MS (SPMS), 2017-2027, $ mn 70
Figure 40. Europe Multiple Sclerosis Drugs Market: Progressive-relapsing MS (PRMS), 2017-2027, $ mn 71
Figure 41. Breakdown of Europe Multiple Sclerosis Drugs Market by Distribution Channel, 2020-2027, % of Revenue 72
Figure 42. Contribution to Europe 2021-2027 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%) 73
Figure 43. Europe Multiple Sclerosis Drugs Market: Hospital Pharmacies, 2017-2027, $ mn 74
Figure 44. Europe Multiple Sclerosis Drugs Market: Retail Pharmacies, 2017-2027, $ mn 75
Figure 45. Europe Multiple Sclerosis Drugs Market: Online Pharmacies, 2017-2027, $ mn 76
Figure 46. Breakdown of European Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue 78
Figure 47. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 79
Figure 48. Multiple Sclerosis Drugs Market in UK, 2017-2027, $ mn 80
Figure 49. Multiple Sclerosis Drugs Market in France, 2017-2027, $ mn 82
Figure 50. Multiple Sclerosis Drugs Market in Germany, 2017-2027, $ mn 84
Figure 51. Multiple Sclerosis Drugs Market in Spain, 2017-2027, $ mn 86
Figure 52. Multiple Sclerosis Drugs Market in Italy, 2017-2027, $ mn 88
Figure 53. Multiple Sclerosis Drugs Market in Russia, 2017-2027, $ mn 90
Figure 54. Multiple Sclerosis Drugs Market in Rest of Europe, 2017-2027, $ mn 92
Figure 55. Growth Stage of Europe Multiple Sclerosis Drugs Industry over the Forecast Period 94

 

Reviews

There are yet no reviews for this product.